ClinicalTrials.gg

Program

episalvan

Also written as “Oleogel-S10”, “AP-101” and “Oleogel-S10, non-adhesive wound dressing”.

Its studies are mostly in Amyotrophic Lateral Sclerosis · Epidermolysis Bullosa · Wounds and Injuries · Epidermolysis Bullosa Dystrophica · Burns, led by 2 companies.

Furthest: phase 3, since Jul 29, 201210 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chiesi Farmaceutici81 open or runningphase 3since Jul 29, 2012Nov 5, 2008none ahead
AL-S Pharma20 open or runningphase 2since Sep 1, 2021May 30, 2019none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 5, 2008First study: phase 2 study in Keratosis, ActinicNew to Chiesi FarmaceuticiChiesi Farmaceutici · NCT00786994 · 165 enrolled · Germany, Greece
  2. Apr 14, 2010Phase 2 study in Accelerating the Epithelialization of Split Thickness Skin GraftChiesi Farmaceutici · NCT01294254 · 24 enrolled · Germany
  3. Oct 27, 2010Phase 2 study in Epidermolysis BullosaChiesi Farmaceutici · NCT01294241 · 10 enrolled · Germany
  4. Jul 29, 20122 phase 3 studiesChiesi Farmaceutici · NCT01657305, NCT01657292
  5. Mar 5, 2013Phase 3 study in Wounds and InjuriesChiesi Farmaceutici · NCT01807650 · 112 enrolled · France, Greece, Latvia and more
  6. Feb 27, 2017Phase 3 study in Epidermolysis BullosaChiesi Farmaceutici · NCT03068780 · 223 enrolled · United States, Argentina, Australia and more
  7. May 30, 2019AL-S Pharma's first study: phase 1 study in Amyotrophic Lateral SclerosisNew to AL-S PharmaAL-S Pharma · NCT03981536 · 18 enrolled · Canada
  8. Sep 1, 2021Phase 2 study in Amyotrophic Lateral SclerosisAL-S Pharma · NCT05039099 · 73 enrolled · United States, Belgium, Canada and more
  9. Mar 17, 2025Phase 3 study in Epidermolysis BullosaChiesi Farmaceutici · NCT06917690 · 6 planned · Japan

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06917690Epidermolysis Bullosa · Japan3RecruitingChiesi FarmaceuticiMar 20266
NCT05039099Amyotrophic Lateral Sclerosis · United States, Belgium, Canada and more2CompletedAL-S PharmaAug 13, 202573
NCT03981536Amyotrophic Lateral Sclerosis · Canada1UNKNOWNAL-S PharmaNov 2, 202018
NCT03068780Epidermolysis Bullosa · United States, Argentina, Australia and more3CompletedChiesi FarmaceuticiJun 11, 2020223
NCT01807650Wounds and Injuries · France, Greece, Latvia and more3CompletedChiesi FarmaceuticiSep 2013112
NCT01657305Wounds and Injuries · Austria, Bulgaria, Czechia and more3CompletedChiesi FarmaceuticiAug 2013107
NCT01657292Burns · Germany, Sweden, Switzerland and more3CompletedChiesi FarmaceuticiJul 201361
NCT01294241Epidermolysis Bullosa · Germany2CompletedChiesi FarmaceuticiJun 201110
NCT01294254Accelerating the Epithelialization of Split Thickness Skin Graft · Germany2CompletedChiesi FarmaceuticiNov 201024
NCT00786994Keratosis, Actinic · Germany, Greece2CompletedChiesi FarmaceuticiNov 2010165

How it is read

Names in the registry

  • “Oleogel-S10”, 4 entries
  • “AP-101”, 2 entries
  • “Oleogel-S10, non-adhesive wound dressing”, 2 entries
  • “Oleogel-S10 ointment”, 1 entry
  • “Oleogel-S10 100 mg/g”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
episalvan (Chiesi Farmaceutici): development program | ClinicalTrials.gg